Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Targeting and stabilizing distinct kinase conformations is an instrumental strategy for
dissecting conformation‐dependent signaling of protein kinases. Herein the structure‐based …

Background: Accumulating data shows that exon 19 deletions and L858R, both activating
epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are …

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet
chemotherapy to the molecular targeted. The major limitation of the targeted therapies still …

Simple Summary This review reports the risk and management of the hepatotoxicity of all the
approved protein kinase inhibitors (PKIs) for cancer. Hepatotoxicity is one of the major safety …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Purpose: Lung cancer remains the leading cause of cancer-related deaths worldwide and
novel therapeutic approaches targeting crucial pathways are urgently needed to improve its …

Purpose We investigated the pattern of rash, diarrhea, and hepatic adverse events (AEs)
secondary to lapatinib and their association with age and pathologic complete response …

Background Gefitinib, erlotinib and afatinib provide remarkable response rates and
progression-free survival compared to platinum-based chemotherapy in patients with non …